{"prompt": "['The investigator must agree to submit all manuscripts or abstracts to the Sponsor prior to', 'submission for publication or presentation. This allows the Sponsor to protect proprietary', 'information and to provide comments based on information from other studies that may not', 'yet be available to the investigator.', 'In accordance with standard editorial and ethical practice, the Sponsor will generally support', 'publication of multicenter trials only in their entirety and not as individual center data. In this', 'case, a coordinating investigator will be designated by mutual agreement.', 'Authorship will be determined by mutual agreement and in line with International Committee', 'of Medical Journal Editors authorship requirements. Any formal publication of the study in', 'which contribution of Sponsor personnel exceeded that of conventional monitoring will be', 'considered as a joint publication by the investigator and the appropriate Sponsor personnel.', 'Any inventions and resulting patents, improvements, and/or know-how originating from the', 'use of data from this study will become and remain the exclusive and unburdened property', 'of the Sponsor, except where agreed otherwise.', '9.6', 'PROTOCOL AMENDMENTS', 'Any protocol amendments will be prepared by the Sponsor. Protocol amendments will be', 'submitted to the IRB/EC and to regulatory authorities in accordance with local regulatory', 'requirements.', 'Approval must be obtained from the IRB/EC and regulatory authorities (as locally required)', 'before implementation of any changes, except for changes necessary to eliminate an', 'immediate hazard to patients or changes that involve logistical or administrative aspects only', '(e.g., change in Medical Monitor or contact information).', '9.7', 'STUDY PARTICIPANT SURVEY', 'Consenting patients may be asked about their study experience via a short study-specific survey.', 'Survey questions will ask the patient to rate their study experience on a scale of 1-5 on topics that', 'include the following: information provided prior to the study, the consent and enrolment process,', 'study participation, study results and feeling appreciated as a study patient.', 'Patients will be asked to complete the survey at the end of the study. The goal of this survey is to', 'identify areas where Roche is performing well and areas where improvement may be required.', 'Information will be provided to the Sponsor securely and on an anonymous basis and consent to the', \"survey is totally voluntary and does not affect patient's enrolment to the study.\", 'Emicizumab - F. Hoffmann-La Roche Ltd', '153 / Protocol MO39129, Version 3']['10.', 'REFERENCES', 'Acharya SS. Rare bleeding disorders in children: identification and primary care', 'management. Pediatrics 2013;132:882-92.', 'Ahnstr\u00f6m J, Berntorp E, Lindvall K, Bj\u00f6rkman S. A 6-year follow-up of dosing, coagulation', 'factor levels and bleedings in relation to joint status in the prophylactic treatment of', 'haemophilia. Haemophilia 2004;10:689-97.', 'Antunes SV, Tangada S, Stasyshyn O, et al. Randomized comparison of prophylaxis and', 'on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors.', 'Haemophilia 2014;20:65-72.', 'Astermark J. When to start and when to stop primary prophylaxis in patients with severe', 'haemophilia. Haemophilia 2003;9 (suppl 1):32-7.', 'Banholzer ML, Buergin H, Wandel C, et al. Clinical trial considerations on male', 'contraception and collection of pregnancy information from female partners. J Transl Med', '2012;10:129.', 'Bell SA, Tudur Smith C. A comparison of interventional clinical trials in rare versus non-rare', 'diseases: an analysis of ClinicalTrials.gov. Orphanet J Rare Dis 2014;9:170.', 'Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A.', 'Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost', '2014;12:1935-9.', 'Brown TM, Lee WC, Joshi AV, Pashos CL. Health-related quality of life and productivity', 'impact in haemophilia patients with inhibitors. Haemophilia 009;15:911-7.', 'Bui JD, Despotis GD, Trulock EP, Patterson GA, Goodnough LT. Fatal thrombosis after', 'administration of activated prothrombin complex concentrates in a patient supported by', 'extracorporeal membrane oxygenation who had received activated recombinant factor VII. J', 'Thorac Cardiovasc Surg 2002;124:852-4.', 'Bullinger M, Von Mackensen S, Fischer K, et al. Pilot testing of the \"Haemo-QoL\\' quality of', 'life questionnaire for haemophiliac children in six European countries. Haemophilia 2002;8', '(suppl 2):47-54.', 'CDC. Centers for Disease Control and Prevention: Hemophilia Data & Statistics. Available', 'from: https://www.cdc.gov/ncbddd/hemophilia/data.html. Last accessed: 17 August 2016', 'Cimino E, Linari S, Malerba M, Halimeh S, Biondo F, Westfeld M. Patient preference and', 'ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-', 'sectional survey in five European countries. Patient Prefer Adherence 2014;8:1713-20.', 'Collins PW, Bj\u00f6rkman S, Fischer K, et al. Factor VIII requirement to maintain a target plasma', 'level in the prophylactic treatment of severe hemophilia A: influences of variance in', 'pharmacokinetics and treatment regimens. J Thromb Haemost 2010;8:269-75.', 'Dentali F, Marchesi C, Pierfranceschi MG, et al. Safety of prothrombin complex concentrates', 'for rapid anticoagulation reversal of vitamin K antagonists: A meta-analysis. Thromb', 'Haemost 2011;106:429-38.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '154 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}